Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
- Mechanism
- Curator reviewed
Lemuteporfin is transported in the plasma primarily by lipoproteins. Once lemuteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of lemuteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclo-oxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction.
- Primary indication
- Intended for the treatment of benign prostatic hyperplasia and prostrate disorders.Curator reviewed
- Formula / weight
- C44H48N4O10 · 792.886 g/mol (avg)
- Code names
- EA 6 · QLT-0074
Resolves to
PUTVMYIZBFOAFU-MTVFQPQZSA-NSMILESCOC(=O)C1C(=CC=C2\C3=C\C4=N\C(=C/C5=C(C)C(CCC(=O)OCCO)=C(N5)\C=C5/N=C(/C=C(\N3)C12C)C(C)=C5CCC(=O)OCCO)\C(C=C)=C4C)C(=O)OCWhat you can answer from here — as of March 26, 2021
Which companies are running trials of Lemuteporfin, in which indications and phases, and which of those programs are still active?